Sichenzia Ross Friedman Ference LLP Attorneys Join Client Oasmia Pharmaceutical AB at NASDAQ Opening Bell Ringing
Press Release – New York, NY – January 11, 2016 – Sichenzia Ross Friedman Ference LLP partners Gregory Sichenzia, Thomas Rose, Henry Nisser and Tara Guarneri-Ferrara and counsel Peter DiChiara joined representatives of client Oasmia Pharmaceutical AB, a developer of a new generation of drugs within human and veterinary oncology, at the NASDAQ MarketSite in Times Square to ring the January 11 opening bell.
They took the stage along with a group of Oasmia Pharmaceutical AB’s leaders, including Executive Chairman Julian Aleksov.
Oasmia Pharmaceutical AB’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company is listed on Nasdaq Stockholm (OASM.ST), Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365) and The Nasdaq Capital Market (OASM.US).
Photographs of the occasion can be viewed by clicking here.
Visit SRFK's LinkedIn page
Latest posts by Sichenzia Ross Ference Kesner LLP (see all)
- Partner Harvey Kesner Publishes Article on US Regulators’ Struggle to Address Cryptocurrenices, ICOs and STOs - June 22, 2018
- Sichenzia Ross Ference Kesner LLP Represents ThinkEquity, a Division of Fordham Financial Management as Sole Book-Running Manager on $18 Million Public Offering of Securities of Trovagene, Inc. - June 12, 2018
- 33/34 Act, M & A Corporate Associate - June 11, 2018